Last updated: 2026-09-05 07:41:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Roivant Sciences Ltd (ROIV) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $34.94, with a market capitalisation of $24.86B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.54 to $37.97. This page covers its latest market performance, valuation, price trends and company information.
$24.86B | |
$34.20 | |
$37.97 | |
$2.52 | |
$34.41 | |
4.24M | |
6.25M | |
-- | |
$37.97 | |
$12.54 | |
-- | |
-- |
Roivant Sciences Ltd (ROIV) last closed at $34.41 as of 2026-09-04 23:59:00, unchanged from the previous close of $34.41.
During the latest regular trading session, ROIV traded between $2.52 and $37.97, with a volume of 4.24M shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Roivant Sciences Ltd (ROIV) moved from $37.58 to $34.94, representing a decline of 7.02% ($2.64).
The stock traded between $33.43 and $37.81 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 11.19 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 88.1%
ROIV is currently trading at $34.94, placing it 88.1% of the way from its 52-week low of $12.54 to its 52-week high of $37.97. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 721 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Roivant Sciences Ltd (ROIV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.